Get the Stockscreener App
12.06
3.52%
-0.44
After Hours:
11.99
-0.07
-0.58%
Adlai Nortye Ltd Adr stock is traded at $12.06, with a volume of 127.80K.
It is down -3.52% in the last 24 hours and up +20.60% over the past month.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
See More
Previous Close:
$12.50
Open:
$13.04
24h Volume:
127.80K
Relative Volume:
0.55
Market Cap:
$776.64M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-11.99
EPS:
-1.0062
Net Cash Flow:
-
1W Performance:
+0.67%
1M Performance:
+20.60%
6M Performance:
+235.00%
1Y Performance:
+737.50%
1-Day Range:
$11.91
$13.04
1-Week Range:
$11.50
$13.50
52-Week Range:
$0.8786
$17.25
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
12.06 | 804.97M | 0 | 0 | 0 | -1.0062 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Leerink Partners | Outperform |
| Feb-13-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-04-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Stock (ANL) Latest News
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025 - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained - TipRanks
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com
Adlai Nortye expands scientific advisory board with two oncologists By Investing.com - Investing.com Nigeria
Adlai Nortye expands scientific advisory board with two oncologists - Investing.com
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – SWB:N2U0 - TradingView
Price to sales forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBIT forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Adlai Nortye Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ANL) - TradingView
Enterprise value to revenue forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating By Investing.com - Investing.com Nigeria
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY) - The Globe and Mail
ANL Stock Price, Quote & Chart | ADLAI NORTYE LTD-ADR (NASDAQ:ANL) - ChartMill
Adlai Nortye initiated with an Outperform at Oppenheimer - TipRanks
Oppenheimer initiates Adlai Nortye stock coverage with Outperform By Investing.com - Investing.com Nigeria
Oppenheimer initiates Adlai Nortye stock coverage with Outperform - Investing.com
ANLAdlai Nortye Ltd ADR Stock Price and Quote - Finviz
Adlai Nortye Ltd. sponsored ADR (ANL) upgraded to buy: Here's what you should know - MSN
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX) - The Globe and Mail
Adlai Nortye CEO Lu Yang sells $131 in company stock By Investing.com - Investing.com Australia
Adlai Nortye CEO Lu Yang sells $131 in company stock - Investing.com
Adlai Nortye initiated with a Buy at JonesResearch - TipRanks
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (ANL), Protagonist Therapeutics (PTGX) and Nuvalent (NUVL) - The Globe and Mail
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Yahoo Finance
Here's why Adlai Nortye Ltd. sponsored ADR (ANL) is a great 'buy the bottom' stock now - MSN
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now - Yahoo! Finance Canada
H.C. Wainwright Sees “Potential Best-in-Class Potency” for Adlai Nortye’s (ANL) Lead Asset, Lifts PT - Yahoo Finance
Adlai Nortye (NASDAQ:ANL) Trading 12.3% HigherHere's Why - MarketBeat
Adlai Nortye (ANL): 10 Tiny Stocks That Are On Fire Right Now - Yahoo Finance
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update - MarketBeat
Is Adlai (ANL) stock a strong investment pick (Volatility Increases) 2026-04-27High Conviction Picks - newsline.com
Adlai Nortye (NASDAQ: ANL) registers $600M shelf; 32.9M ADS resale - Stock Titan
Adlai Nortye (NASDAQ:ANL) Shares Gap DownTime to Sell? - MarketBeat
Adlai Nortye FY2026 EPS Forecast Raised by HC Wainwright - MarketBeat
Adlai Nortye (NASDAQ:ANL) Sets New 1-Year HighStill a Buy? - MarketBeat
Adlai Nortye price target raised to $20 from $16 at H.C. Wainwright - TipRanks
Adlai (ANL) Stock Rallies on Launch (Smart Money Exits) 2026-04-20Modified Schiff - The Legal Advocate
Adlai Nortye (NASDAQ:ANL) Stock Price Up 18.1%What's Next? - MarketBeat
Adlai Nortye raises $150M in oversubscribed private placement By Investing.com - Investing.com India
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing - Sahm
Adlai Nortye Raises $150 Million in Oversubscribed Private Placement to Advance Cancer Pipeline - TipRanks
Adlai Nortye Ltd Adr Stock (ANL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):